A putative competing endogenous RNA network in cisplatin-resistant lung adenocarcinoma cells identifying potentially rewarding research targets

Lung adenocarcinoma (LUAD) is the most common type of non-small cell lung cancer and has a poor 5 year survival rate (<10%). Cisplatin is one of the most effective chemotherapeutic treatments for LUAD, even though it is of limited overall utility due to acquired drug resistance. To identify possi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yepeng, Huang, Shiqing, Wei, Zhongheng, Yang, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202328/
https://www.ncbi.nlm.nih.gov/pubmed/32382346
http://dx.doi.org/10.3892/ol.2020.11483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202328/
https://www.ncbi.nlm.nih.gov/pubmed/32382346
http://dx.doi.org/10.3892/ol.2020.11483

Ejemplares similares